{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T19:28:22Z","timestamp":1769196502901,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00520-022-06968-w","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T22:02:21Z","timestamp":1647640941000},"page":"5431-5440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study"],"prefix":"10.1007","volume":"30","author":[{"given":"C\u00e9cile","family":"Conte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Vayr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christelle","family":"Pajiep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Despas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryse Lapeyre","family":"Mestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5338-2071","authenticated-orcid":false,"given":"Martin","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Herin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"issue":"1","key":"6968_CR1","doi-asserted-by":"publisher","first-page":"e187147","DOI":"10.1001\/jamanetworkopen.2018.7147","volume":"2","author":"MJ Jabagi","year":"2019","unstructured":"Jabagi MJ, Vey N, Goncalves A, Le Tri T, Zureik M, Dray-Spira R (2019) Evaluation of the incidence of hematologic malignant neoplasms among breast cancer survivors in France. JAMA Netw Open 2(1):e187147. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.7147","journal-title":"JAMA Netw Open"},{"key":"6968_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00277-015-2331-1","volume":"94","author":"R Hehlmann","year":"2015","unstructured":"Hehlmann R (2015) CML\u2014where do we stand in 2015? Ann Hematol 94:103\u2013105. https:\/\/doi.org\/10.1007\/s00277-015-2331-1","journal-title":"Ann Hematol"},{"issue":"24","key":"6968_CR3","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34(24):2851\u20132857. https:\/\/doi.org\/10.1200\/JCO.2015.66.2866","journal-title":"J Clin Oncol"},{"issue":"10","key":"6968_CR4","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"MW Deininger","year":"2020","unstructured":"Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B et al (2020) Chronic Myeloid Leukemia, version 2.2021, NCCN clinical practice guidelines in Oncology. J Natl Compr Canc Netw. 18(10):1385\u20131415. https:\/\/doi.org\/10.6004\/jnccn.2020.0047","journal-title":"J Natl Compr Canc Netw."},{"issue":"15","key":"6968_CR5","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, International Randomised Study of Interferon\u00a0versus STI571 (IRIS) Study Group (2003) Frequency of major molecular responses to imatinib or interferon alfa pluscytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349(15):1423\u20131432. https:\/\/doi.org\/10.1056\/NEJMoa030513","journal-title":"N Engl J Med"},{"key":"6968_CR6","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, LeukemiaNet E et al (2020) recommendations for treating chronic myeloid leukemia. Leukemia 34:966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"6968_CR7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa022457","journal-title":"N Engl J Med"},{"issue":"20","key":"6968_CR8","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A (2016) Final 5-year study results of dasision: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol 34(20):2333\u20132340. https:\/\/doi.org\/10.1200\/JCO.2015.64.8899","journal-title":"J Clin Oncol"},{"issue":"1","key":"6968_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3324\/haematol.2018.188987","volume":"104","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE (2019) Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica 104(1):93\u2013101. https:\/\/doi.org\/10.3324\/haematol.2018.188987","journal-title":"Haematologica"},{"issue":"11","key":"6968_CR10","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s00277-018-3412-8","volume":"97","author":"I Fujioka","year":"2018","unstructured":"Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T (2018) Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol 97(11):2081\u20132088. https:\/\/doi.org\/10.1007\/s00277-018-3412-8","journal-title":"Ann Hematol"},{"key":"6968_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.exphem.2018.08.006","volume":"67","author":"M Heiblig","year":"2018","unstructured":"Heiblig M, Rea D, Chr\u00e9tien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Am\u00e9 S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE (2018) Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study. Exp Hematol 67:41\u201348. https:\/\/doi.org\/10.1016\/j.exphem.2018.08.006","journal-title":"Exp Hematol"},{"issue":"6","key":"6968_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/14740338.2018.1480719","volume":"17","author":"M Breccia","year":"2018","unstructured":"Breccia M, Efficace F, Iurlo A, Luciano L, Abruzzese E, Gozzini A, Pregno P, Tiribelli M, Rosti G, Minotti G (2018) Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. Expert Opin Drug Saf 17(6):623\u2013628. https:\/\/doi.org\/10.1080\/14740338.2018.1480719","journal-title":"Expert Opin Drug Saf"},{"key":"6968_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.clml.2013.05.012","volume":"13","author":"E Jabbour","year":"2013","unstructured":"Jabbour E, Lipton JH (2013) A critical review of trials of first-line bcr-abl inhibitor treatment in patients with newly diagnosed Chronic Myeloid Leukemia in chronic phase. Clin Lymphoma Myeloma Leuk 13:646\u2013656. https:\/\/doi.org\/10.1016\/j.clml.2013.05.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"6968_CR14","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM (2016) Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30(5):1044\u20131054. https:\/\/doi.org\/10.1038\/leu.2016.5","journal-title":"Leukemia"},{"issue":"6","key":"6968_CR15","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","volume":"3","author":"P Jain","year":"2019","unstructured":"Jain P, Kantarjian H, Boddu PC, Nogueras-Gonz\u00e1lez GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O\u2019Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE (2019) Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv 3(6):851\u2013861. https:\/\/doi.org\/10.1182\/bloodadvances.2018025874","journal-title":"Blood Adv"},{"issue":"6","key":"6968_CR16","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2013.69","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, Hochhaus A, le Coutre PD, Saglio G (2013) Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 27(6):1310\u20131315. https:\/\/doi.org\/10.1038\/leu.2013.69","journal-title":"Leukemia"},{"issue":"8","key":"6968_CR17","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.3109\/10428194.2014.994205","volume":"56","author":"J Gora-Tybor","year":"2015","unstructured":"Gora-Tybor J, Medras E, Calbecka M, Kolkowska-Le\u015bniak A, Ponikowska-Szyba E, Robak T, Jamroziak K (2015) Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. Leuk Lymphoma 56(8):2309\u20132314. https:\/\/doi.org\/10.3109\/10428194.2014.994205","journal-title":"Leuk Lymphoma"},{"key":"6968_CR18","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/02841860903229124","volume":"48","author":"GS Orphanos","year":"2009","unstructured":"Orphanos GS, Ioannidis GN, Ardavanis AG (2009) Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 48:964\u2013970. https:\/\/doi.org\/10.1080\/02841860903229124","journal-title":"Acta Oncol"},{"issue":"1","key":"6968_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14740338.2017.1261824","volume":"16","author":"H Haguet","year":"2017","unstructured":"Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogn\u00e9 JM (2017) Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf 16(1):5\u201312. https:\/\/doi.org\/10.1080\/14740338.2017.1261824","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"6968_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s12185-017-2225-1","volume":"106","author":"KJ Suh","year":"2017","unstructured":"Suh KJ, Lee JY, Shin DY, Koh Y, Bang SM, Yoon SS, Park S, Kim I, Lee JO (2017) Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials. Int J Hematol 106(2):229\u2013239. https:\/\/doi.org\/10.1007\/s12185-017-2225-1","journal-title":"Int J Hematol"},{"issue":"4","key":"6968_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11936-017-0524-8","volume":"19","author":"R Damrongwatanasuk","year":"2017","unstructured":"Damrongwatanasuk R, Fradley MG (2017) Cardiovascular complications of targeted therapies for chronic myeloid leukemia. Curr Treat Options Cardiovasc Med 19(4):24. https:\/\/doi.org\/10.1007\/s11936-017-0524-8","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"6968_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejon.2008.01.006","volume":"12","author":"Z Amir","year":"2008","unstructured":"Amir Z, Neary D, Luker K (2008) Cancer survivors\u2019 views of work 3 years post diagnosis: a UK perspective. Eur J Oncol Nurs 12:190\u2013197. https:\/\/doi.org\/10.1016\/j.ejon.2008.01.006","journal-title":"Eur J Oncol Nurs"},{"key":"6968_CR23","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2018.374","author":"MS Islam","year":"2018","unstructured":"Islam MS (2018) Treat patient, not just the disease: holistic needs assessment for haematological cancer patients. Oncol Rev. https:\/\/doi.org\/10.4081\/oncol.2018.374","journal-title":"Oncol Rev"},{"issue":"5","key":"6968_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3109\/0284186X.2014.999871","volume":"54","author":"TA Horsboel","year":"2015","unstructured":"Horsboel TA, Nielsen CV, Nielsen B, Andersen NT, De Thurah A (2015) Wage-subsidised employment as a result of permanently reduced work capacity in a nationwide cohort of patients diagnosed with haematological malignancies. Acta Oncol 54(5):743\u2013749. https:\/\/doi.org\/10.3109\/0284186X.2014.999871","journal-title":"Acta Oncol"},{"issue":"6","key":"6968_CR25","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3109\/0284186X.2013.875625","volume":"53","author":"TA Horsboel","year":"2014","unstructured":"Horsboel TA, Nielsen CV, Andersen NT, Nielsen B, de Thurah A (2014) Risk of disability pension for patients diagnosed with haematological malignancies: a register-based cohort study. Acta Oncol 53(6):724\u2013734. https:\/\/doi.org\/10.3109\/0284186X.2013.875625","journal-title":"Acta Oncol"},{"issue":"3","key":"6968_CR26","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00277-018-3549-5","volume":"98","author":"S De Barros","year":"2019","unstructured":"De Barros S, Vayr F, Despas F, Strumia M, Podevin C, Gauthier M, Delabesse E, Soulat JM, Laurent G, Huguet F, Herin F (2019) The impact of chronic myeloid leukemia on employment: the French prospective study. Ann Hematol 98(3):615\u2013623. https:\/\/doi.org\/10.1007\/s00277-018-3549-5","journal-title":"Ann Hematol"},{"issue":"2","key":"6968_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.therap.2018.09.076","volume":"74","author":"C Conte","year":"2019","unstructured":"Conte C, Vaysse C, Bosco P, Noize P, Fourrier-Reglat A, Despas F, Lapeyre-Mestre M (2019) The value of a health insurance database to conduct pharmacoepidemiological studies in oncology. Therapie 74(2):279\u2013288. https:\/\/doi.org\/10.1016\/j.therap.2018.09.076","journal-title":"Therapie"},{"issue":"8","key":"6968_CR28","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, Moore N (2017) The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf 26(8):954\u2013962. https:\/\/doi.org\/10.1002\/pds.4233","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"6968_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.revmed.2014.11.009","volume":"36","author":"G Moulis","year":"2015","unstructured":"Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc JL, Sailler L (2015) French health insurance databases: what interest for medical research? Rev Med Interne 36(6):411\u2013417. https:\/\/doi.org\/10.1016\/j.revmed.2014.11.009","journal-title":"Rev Med Interne"},{"issue":"1","key":"6968_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/fcp.12592","volume":"35","author":"E Casarotto","year":"2021","unstructured":"Casarotto E, Noize P, Gouverneur A, Berda\u00ef D, B\u00e9gaud B, Levy-Bachelot L, Molimard M (2021) Overview of French databases available for studying anticancer drugs in real-life setting. Fundam Clin Pharmacol 35(1):76\u201385. https:\/\/doi.org\/10.1111\/fcp.12592","journal-title":"Fundam Clin Pharmacol"},{"issue":"5","key":"6968_CR31","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/fcp.12544","volume":"34","author":"M Gauthier","year":"2020","unstructured":"Gauthier M, Conte C, Palmaro A, Patras De Campaigno E, De Barros S, Huguet F, Laurent G, Lapeyre-Mestre M, Despas F (2020) Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia: a population-based study in France. Fundam Clin Pharmacol 34(5):612\u2013622. https:\/\/doi.org\/10.1111\/fcp.12544","journal-title":"Fundam Clin Pharmacol"},{"issue":"11","key":"6968_CR32","doi-asserted-by":"publisher","first-page":"675609","DOI":"10.3389\/fonc.2021.675609","volume":"30","author":"M Pajiep","year":"2021","unstructured":"Pajiep M, Conte C, Huguet F, Gauthier M, Despas F, Lapeyre-Mestre M (2021) Patterns of tyrosine-kinase inhibitor utilization in newly treated patients with chronic myeloid leukemia: an exhaustive population-based study in France. Front Oncol 30(11):675609. https:\/\/doi.org\/10.3389\/fonc.2021.675609","journal-title":"Front Oncol"},{"issue":"2","key":"6968_CR33","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","volume":"54","author":"A Bannay","year":"2016","unstructured":"Bannay A, Chaignot C, Bloti\u00e8re PO, Basson M, Weill A, Ricordeau P, Alla F (2016) The best use of the Charlson comorbidity index with electronic health care database to predict mortality. Med Care 54(2):188\u2013194. https:\/\/doi.org\/10.1097\/MLR.0000000000000471","journal-title":"Med Care"},{"issue":"17","key":"6968_CR34","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Barat\u00e8 C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F, GIMEMA (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118(17):4554\u20134560. https:\/\/doi.org\/10.1182\/blood-2011-04-347575","journal-title":"Blood"},{"issue":"8","key":"6968_CR35","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garc\u00eda-Guti\u00e9rrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, Hehlmann R, Clark RE (2016) European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30(8):1648\u20131671. https:\/\/doi.org\/10.1038\/leu.2016.104","journal-title":"Leukemia"},{"issue":"6","key":"6968_CR36","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1002\/cam4.2200","volume":"8","author":"S Foulon","year":"2019","unstructured":"Foulon S, Cony-Makhoul P, Guerci-Bresler A, Delord M, Solary E, Monnereau A, Bonastre J, Tubert-Bitter P (2019) Using healthcare claims data to analyze the prevalence of BCR-ABL-positive chronic myeloid leukemia in France: a nationwide population-based study. Cancer Med 8(6):3296\u20133304. https:\/\/doi.org\/10.1002\/cam4.2200","journal-title":"Cancer Med"},{"issue":"11","key":"6968_CR37","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","volume":"21","author":"EA Hahn","year":"2003","unstructured":"Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O\u2019Brien SG, Dobrez DG, Hensley ML, Cella D, IRIS Investigators (2003) Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21(11):2138\u20132146. https:\/\/doi.org\/10.1200\/JCO.2003.12.154","journal-title":"J Clin Oncol"},{"issue":"14","key":"6968_CR38","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1002\/cncr.31411","volume":"124","author":"D Rea","year":"2018","unstructured":"Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, Cony-Makhoul P, Dubruille V, Dulucq S, Etienne G, Legros L, Nicolini F, Roche-Lestienne C, Escoffre-Barbe M, Gardembas M, Guerci-Bresler A, Johnson-Ansah H, Rigal-Huguet F, Rousselot P, Mahon FX, French Chronic Myeloid Leukemia Study Group (2018) Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group. Cancer 124(14):2956\u20132963. https:\/\/doi.org\/10.1002\/cncr.31411","journal-title":"Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06968-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-06968-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06968-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T21:04:42Z","timestamp":1651093482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-06968-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["6968"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-06968-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"assertion":[{"value":"31 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study obtained a favorable opinion from the Institute of Health Data (Approval No. 165 of November 24, 2015), and from the French National Agency regulating Data Protection on December 24, 2015 (DE-2015\u2013119).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Data included in the SNDS are always anonymized and comply with the French Legislation about confidentiality and data protection (law \u2018Informatique et Libert\u00e9s\u2019 du 6 janvier 1978). Thus, participants cannot be identified and it is not possible to ask for informed consent from the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Data included in the SNDS are always anonymized and comply with the French Legislation about confidentiality and data protection (law \u2018Informatique et Libert\u00e9s\u2019 du 6 janvier 1978). Thus, participants cannot be identified and it is not possible to ask for informed consent from the participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FHu: Honoraria from Incyte, Novartis and Pfizer. The remaining authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}